Receptor recognition mechanisms of coronaviruses
冠状病毒的受体识别机制
基本信息
- 批准号:8651407
- 负责人:
- 金额:$ 37.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-15 至 2015-04-30
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAnimalsAntiviral AgentsBindingBiochemicalBiological AssayCell fusionCellsComplexCoronavirusCoronavirus InfectionsCoronavirus spike proteinDevelopmentElementsEpidemicEvolutionFamily FelidaeFamily suidaeFeline infectious peritonitis virusFutureHealthHumanInfectionInterventionLeadMedicalMolecularMonitorMutagenesisMutationNon-Human ProteinPattern recognition receptorPeptidyl-Dipeptidase APreventionProteinsResearchSARS coronavirusSequence HomologySevere Acute Respiratory SyndromeSpecificitySpottingsStructural ModelsStructureSurface Plasmon ResonanceTestingTransmissible gastroenteritis virusViralVirusVirus DiseasesVirus ReceptorsViverridaealanine aminopeptidasebasecomparativecoronavirus receptorimprovedinsightnovelnovel strategiespublic health relevancereceptorreceptor bindingrespiratory virustool
项目摘要
DESCRIPTION (provided by applicant): Receptor recognition by viruses is the first and essential step of viral infections. It is an important determinant of viral host ranges and cross-species infections, and a primary target for human intervention. Coronaviruses recognize a variety of receptors, infect many hosts, and are significant health threats to humans and other animals. NL63 coronavirus (NL63-CoV), a prevalent human respiratory virus, is the only group-I coronavirus known to use angiotensin-converting enzyme 2 (ACE2) as its receptor, whereas other group-I coronaviruses use aminopeptidase-N (APN). Curiously, ACE2 is also used by group-II SARS coronavirus (SARS-CoV), the agent for the fatal human severe acute respiratory syndrome (SARS). Defined receptor-binding domains (RBDs) on the spike proteins of NL63-CoV and SARS-CoV bind ACE2 with high affinity. This research investigates the receptor recognition mechanisms and cross-species infections of coronaviruses. Our preliminary studies have determined the crystal structures of NL63-CoV RBD complexed with human ACE2 and of SARS-CoV RBD complexed with human ACE2. NL63-CoV and SARS-CoV RBDs have no structural homology in cores or receptor-binding motifs (RBMs) that directly contact ACE2, but recognize the same "virus-binding hotspot" on ACE2. Among group-I coronaviruses, RBD cores are conserved, but RBMs are variable, explaining how these viruses recognize different receptors. We have also determined crystal structures of the RBDs from various SARS-CoV strains complexed with ACE2 proteins from humans and palm civets, revealing mechanisms whereby SARS-CoV transmitted between the two hosts. There are three specific aims in this project. Aim 1 focuses on the receptor recognition mechanisms of group-I NL63-CoV. It investigates specific functions of the virus-binding hotspot on human ACE2 in NL63-CoV binding, and examines interactions between the NL63-CoV spike protein and ACE2 proteins from non-human hosts. Aim 2 focuses on the receptor recognition mechanisms of other group-I coronaviruses. It investigates specific functions of the RBMs of other group-I coronavirus spike proteins, and studies whether modifying the RBMs changes the receptor specificities of the spike proteins. Aim 3 focuses on the receptor recognition mechanisms of group-II SARS-CoV. It investigates why mutations in the RBM region of past SARS-CoV strains were selected, whether and how these mutations affect receptor binding, and what combinations of these mutations may appear in potential future SARS-CoV strains. The research approaches of this proposal include crystallographic analysis of the virus-receptor interfaces, identification of structural elements important for virus-receptor interactions, and characterization of these elements using crystallographic, biochemical, molecular, and virological tools. Overall, these studies will provide the molecular and structural basis for understanding viral evolution, virus-receptor interactions, viral host ranges and cross-species infections. They will also guide the development of novel antiviral strategies against coronavirus infections.
描述(由申请人提供):病毒对受体的识别是病毒感染的第一步也是必不可少的一步。它是病毒宿主范围和跨物种感染的重要决定因素,也是人类干预的主要目标。冠状病毒可以识别多种受体,感染许多宿主,对人类和其他动物的健康构成重大威胁。NL63冠状病毒(NL63- cov)是一种流行的人类呼吸道病毒,是已知唯一以血管紧张素转换酶2 (ACE2)为受体的i族冠状病毒,而其他i族冠状病毒则使用氨基肽酶n (APN)。奇怪的是,导致致命的人类严重急性呼吸系统综合征(SARS)的病原体——ii类SARS冠状病毒(SARS- cov)也使用ACE2。NL63-CoV和SARS-CoV刺突蛋白上的受体结合域(rbd)与ACE2具有高亲和力。本研究对冠状病毒的受体识别机制和跨种感染进行了研究。我们的初步研究已经确定了NL63-CoV RBD与人ACE2复合物和SARS-CoV RBD与人ACE2复合物的晶体结构。NL63-CoV和SARS-CoV的rbd在直接接触ACE2的核心或受体结合基元(RBMs)上没有结构同源性,但在ACE2上识别相同的“病毒结合热点”。在i族冠状病毒中,RBD核心是保守的,但RBD是可变的,这解释了这些病毒如何识别不同的受体。我们还确定了各种SARS-CoV菌株RBDs与人类和棕榈果子狸ACE2蛋白复合物的晶体结构,揭示了SARS-CoV在两种宿主之间传播的机制。这个项目有三个具体目标。目的1:研究NL63-CoV的受体识别机制。研究病毒结合热点在NL63-CoV与人ACE2结合中的具体功能,以及NL63-CoV刺突蛋白与非人宿主ACE2蛋白的相互作用。第二部分主要研究其他一类冠状病毒的受体识别机制。研究其他一类冠状病毒刺突蛋白rbm的特异性功能,并研究修饰rbm是否会改变刺突蛋白的受体特异性。目的3研究ii族SARS-CoV的受体识别机制。它调查了过去SARS-CoV毒株RBM区域的突变为何被选择,这些突变是否以及如何影响受体结合,以及这些突变的哪些组合可能出现在潜在的未来SARS-CoV毒株中。本建议的研究方法包括病毒-受体界面的晶体学分析,识别病毒-受体相互作用的重要结构元件,以及使用晶体学,生化,分子和病毒学工具表征这些元件。总的来说,这些研究将为了解病毒进化、病毒-受体相互作用、病毒宿主范围和跨物种感染提供分子和结构基础。他们还将指导开发针对冠状病毒感染的新型抗病毒策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fang Li其他文献
Fang Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fang Li', 18)}}的其他基金
Targeting ATM to boost systemic effects of radiotherapy and immunotherapy
靶向 ATM 以增强放射治疗和免疫治疗的全身效应
- 批准号:
10586034 - 财政年份:2021
- 资助金额:
$ 37.37万 - 项目类别:
Targeting apoptotic caspases to enhance cancer radiotherapy
靶向凋亡半胱天冬酶以增强癌症放射治疗
- 批准号:
10305613 - 财政年份:2017
- 资助金额:
$ 37.37万 - 项目类别:
Necroptotic genes in cancer cellular response to radiation
癌细胞对辐射反应中的坏死性凋亡基因
- 批准号:
10089416 - 财政年份:2017
- 资助金额:
$ 37.37万 - 项目类别:
Receptor recognition and cell entry of coronaviruses
冠状病毒的受体识别和细胞进入
- 批准号:
9174759 - 财政年份:2016
- 资助金额:
$ 37.37万 - 项目类别:
MOUSE HEPATITIS CORONAVIRUS RECEPTOR-BINDING DOMAIN
小鼠肝炎冠状病毒受体结合域
- 批准号:
8361713 - 财政年份:2011
- 资助金额:
$ 37.37万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 37.37万 - 项目类别:
Continuing Grant